Literature DB >> 26254392

Strategies for Preventing Pseudomyxoma Peritonei After Resection of a Mucinous Neoplasm of the Appendix.

Charles Honoré1, Francesco Caruso2, Peggy Dartigues3, Léonor Benhaim2, Mircea Chirica2, Diane Goéré2, Dominique Elias2.   

Abstract

BACKGROUND/AIM: Considering the suspected link between mucinous neoplasm (MN) and pseudomyxoma peritonei (PMP), one option could be to propose prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) to selected patients in order to prevent the occurrence of PMP. The aim of this study was to identify risk factors for developing PMP after curative surgery for a MN of the appendix. PATIENTS AND METHODS: All consecutive patients referred to our single tertiary care cancer center between September 1992 and March 2014 for MN of the appendix, initially without PMP, were retrospectively studied. Patients who had received prophylactic intraperitoneal treatment were excluded from the analysis.
RESULTS: Twenty-five patients with a median age of 51 (range=25-74) years were identified. At the initial appendectomy, 19 (76%) patients had a perforated MN. Nine of these patients (40%) exhibited disseminated-free acellular intraperitoneal mucin without PMP. Six (24%) patients had an unperforated MN without free intraperitoneal mucin. After a median follow-up of 50 months, 12 (52%) patients had developed PMP after a median time of 61 (range=13-121) months. Complete cytoreductive surgery plus HIPEC was possible in only seven (64%) out of these 12 patients. No factor reached statistical significance in predicting the occurrence of PMP but a trend was found in the case of perforated MN (p=0.068), associated with a 65% recurrence rate, compared to 17% without perforation.
CONCLUSION: An appendicular MN cannot be considered a benign occurrence because PMP is common after resection and can occur up to 10 years after the initial appendectomy. Patients should be systematically followed up to detect PMP as early as possible. Patients with a perforated MN could be at higher risk of developing PMP. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  HIPEC; Pseudomyxoma peritonei; mucinous neoplasm; mucocele; perforated appendix; peritoneal carcinomatosis

Mesh:

Year:  2015        PMID: 26254392

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

1.  Cellularity in low-grade Pseudomyxoma peritonei impacts recurrence-free survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Philipp Horvath; Can Yurttas; Philipp Birk; Florian Struller; Alfred Königsrainer
Journal:  Langenbecks Arch Surg       Date:  2018-12-01       Impact factor: 3.445

2.  A Multi-institutional Study of Peritoneal Recurrence Following Resection of Low-grade Appendiceal Mucinous Neoplasms.

Authors:  Joel M Baumgartner; Amitabh Srivastava; Nelya Melnitchouk; Michael G Drage; Aaron R Huber; Raul S Gonzalez; Phoenix Bell; Elizabeth Wu; Murray Resnick; Kiran Turaga; Elizabeth Poli; Jesus Esquivel; Jeremiah Deneve; Kaitlyn J Kelly; Jula Veerapong; Andrew M Lowy
Journal:  Ann Surg Oncol       Date:  2021-01-07       Impact factor: 5.344

Review 3.  Recurrence of initially localized appendiceal mucinous neoplasms after radical resection: survey analysis and literature review.

Authors:  Toshiyuki Kitai; Yutaka Yonemura
Journal:  Int J Clin Oncol       Date:  2022-03-09       Impact factor: 3.402

4.  Histopathological discrepancy and variation of surgical management in mucinous ovarian cystadenoma and pseudomyxoma peritonei.

Authors:  Gatot Purwoto; Tricia Dewi Anggraeni; Primariadewi Rustamadji; Ilham Utama Surya; Kelli Julianti; Nathaniel Herlambang
Journal:  Int J Surg Case Rep       Date:  2022-05-03

5.  Laparoscopic cytoreductive surgery and HIPEC in LAMN with small volume of peritoneal disease: a valuable option of treatment for good patient-related experience measures (PREMs).

Authors:  Caterina Cusumano; Sébastien Carrere; Alix Bouillin; Stéphanie Nougaret; Lakhdar Khellaf; François Quénet; Olivia Sgarbura
Journal:  Surg Endosc       Date:  2021-11-29       Impact factor: 3.453

6.  Risk of Appendiceal Neoplasm in Periappendicular Abscess in Patients Treated With Interval Appendectomy vs Follow-up With Magnetic Resonance Imaging: 1-Year Outcomes of the Peri-Appendicitis Acuta Randomized Clinical Trial.

Authors:  Jari Mällinen; Tero Rautio; Juha Grönroos; Tuomo Rantanen; Pia Nordström; Heini Savolainen; Pasi Ohtonen; Saija Hurme; Paulina Salminen
Journal:  JAMA Surg       Date:  2019-03-01       Impact factor: 14.766

Review 7.  Proactive Management for Gastric, Colorectal and Appendiceal Malignancies: Preventing Peritoneal Metastases with Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Authors:  Paolo Sammartino; Daniele Biacchi; Tommaso Cornali; Maurizio Cardi; Fabio Accarpio; Alessio Impagnatiello; Bianca Maria Sollazzo; Angelo Di Giorgio
Journal:  Indian J Surg Oncol       Date:  2016-01-26

8.  Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei and Appendix Tumours.

Authors:  Joshua Lansom; Nayef Alzahrani; Winston Liauw; David L Morris
Journal:  Indian J Surg Oncol       Date:  2015-10-24

Review 9.  Essentials for Pathological Evaluation of Peritoneal Surface Malignancies and Synoptic Reporting of Cytoreductive Surgery Specimens-A review and evidence-based guide.

Authors:  Aditi Bhatt; Suniti Mishra; Loma Parikh; Sandeep Sheth; Imran Gorur
Journal:  Indian J Surg Oncol       Date:  2019-03-19

10.  The role of mucin cell-free DNA detection as a new marker for the study of acellular pseudomyxoma peritonei of appendicular origin by liquid biopsy.

Authors:  Damián García-Olmo; Susana Olmedillas-López; Delia Cortés-Guiral; Pedro Villarejo; Irene López Rojo; Héctor Guadalajara; Soledad García Gómez-Heras; Mariano García-Arranz
Journal:  Ther Adv Med Oncol       Date:  2020-06-24       Impact factor: 8.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.